Neuronetics (FRA:NRC) 3-Year EPS without NRI Growth Rate : 9.40% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Neuronetics 3-Year EPS without NRI Growth Rate?

Neuronetics's EPS without NRI for the three months ended in Dec. 2023 was €-0.17.

During the past 3 years, the average EPS without NRI Growth Rate was 9.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Neuronetics was 90.00% per year. The lowest was 4.40% per year. And the median was 23.20% per year.

Competitive Comparison of Neuronetics's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, Neuronetics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuronetics's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Neuronetics's 3-Year EPS without NRI Growth Rate falls into.

Neuronetics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Neuronetics (FRA:NRC) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Neuronetics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Neuronetics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuronetics (FRA:NRC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (FRA:NRC) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

STIM:USA NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.